Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
143
resultados
Última actualización
25/04/2025 [06:59:00]
Resultados 100 a 125 de 143
Resumen de: WO2024233362A1
Provided herein are methods of treating an inflammatory bowel disease (IBD) in a subject by administering to the subject a thiopurine drug for the treatment of IBD, the subject not comprising an at risk genetic variant or serological marker. Also provided herein are related compositions, uses, system, and kits.
Resumen de: EP4417707A2
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.
Resumen de: WO2024228570A1
The present invention relates to discovery of a target for inhibiting fibrosis in inflammatory bowel disease, and prediction of the progression of fibrosis in inflammatory bowel disease by using same. The present inventors, who are researchers, have found that NOX4 transcripts are detected at low levels in a normal colon, but NOX4 expression is up-regulated in drug-resistant fibrostenosis patients with UC or Crohn's disease (CD) and in a dextran sulfate sodium (DSS)-induced mouse colitis model, and thus it is hypothesized that NOX4 contributes to intestinal fibrosis damage of ulcerative colitis and TGF-β signaling is required to induce fibrosis development. In order to test this hypothesis, the present inventors established Nox4 deficient mice (Nox4-/-) with DSS-induced colitis, and investigated the effect of Nox4 on the response to intestinal injury. This study is expected to be widely used to predict whether fibrosis proceeds in inflammatory bowel diseases and inhibit same.
Resumen de: CN118924920A
The invention discloses a neutrophil elastase activated near-infrared two-region fluorescent carbon dot and application thereof in diagnosis of inflammatory bowel diseases. The neutrophil elastase activated near-infrared two-region fluorescent carbon dot is obtained by combining a carbon dot synthesized by a solvothermal method with pentafluoropropionic anhydride through a covalent bond. The carbon dot disclosed by the invention can perform specific and sensitive response on neutrophil elastase with high biocompatibility in cells and in vivo, shows a strong NIR-II fluorescence signal, and can be used for real-time imaging of noninvasive diagnosis evaluation of early inflammatory bowel diseases; and a potential method is provided for developing a clinical non-invasive early inflammatory bowel disease diagnosis technology.
Resumen de: US2023203591A1
Provided herein are materials and methods for isolation of eukaryotic nucleic acid from a human or non-human animal stool sample. Also provided are methods of analysis of eukaryotic biomarkers present in a human or non-human animal stool sample.
Resumen de: MX2024011979A
The disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q)or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient: Also provided are dosage units comprising one or more of compound (A), compound (B), compound (C), compound (D), compound (E), compound (F), compound (G), compound (H), compound (J), compound (K), compound (L), compound (M), compound (N), compound (O), compound (P), or compound (Q) or the pharmaceutical compositions described herein, methods of treating an inflammatory bowel disease in a subject in need thereof, or methods of modulating an inflammatory bowel disease marker in a subject in need thereof.
Resumen de: CN118909916A
Disclosed herein are methods for the in vitro differentiation of precursor cells into definitive endoderm by modulating the signaling pathway, which definitive endoderm can be further differentiated into human colon organoids (HCOs). Further disclosed are HCOs and methods of using HCOs, which may be used, for example, for HCOs to determine the efficacy and/or toxicity of potential therapeutic agents against a disease selected from the group consisting of colitis, colon cancer, polyp syndrome and/or irritable bowel syndrome.
Resumen de: JP2024159821A
To provide methods and treatment involving excess free LIGHT.SOLUTION: The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT and to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. The conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), where the ALI and ARDS are optionally associated with viral infection, including coronavirus infection. The conditions also include Crohn's disease or an inflammatory condition associated with Crohn's disease.SELECTED DRAWING: Figure 10
Resumen de: CN118910292A
The invention relates to a biomarker for diagnosis of VEO-IBD and IL10RA mutation enteritis. The defects that in the prior art, existing IBD diagnosis mostly depends on blood detection, endoscope and other invasive and invasive examinations, the screening detection threshold is high, certain risks exist, the medical compliance is poor, and misdiagnosis and missed diagnosis are likely to happen are overcome.
Resumen de: CN118903262A
The invention provides radix paeoniae alba and semen raphani bowel-relaxing granules as well as a preparation method and a quality detection method thereof. The radix paeoniae alba and semen raphani bowel-relaxing granules are prepared from the following raw material medicines in parts by weight: 800 to 1200 parts of fried radix paeoniae alba, 800 to 1200 parts of fried semen raphani and 200 to 350 parts of fructus cannabis. Weighing parched white peony roots, parched radish seeds and fructus cannabis, adding water to decoct, filtering, combining filtrate obtained by filtering each time, and concentrating under reduced pressure; weighing dextrin, putting the dextrin into a fluidized bed, setting the air inlet amount and the air inlet temperature, and atomizing and drying the concentrated solution to obtain the paeonia lactiflora laxative granules. The quality detection method consists of identification and content determination, the identification is to identify parched white peony root and parched radish seed by utilizing a thin layer chromatography, and the content determination is to determine the content of parched white peony root in the paeonia lactiflora laxative granules by utilizing a high performance liquid chromatography. The paeonia lactiflora laxative granules prepared by the invention are mild in drug property, do not contain anthraquinone components, and dredge the body without hurting healthy qi. The quality detection method is high in accuracy, and the medici
Resumen de: CN118910056A
The invention belongs to the technical field of animal genetic engineering, and particularly relates to a small interfering RNA for regulating and controlling the barrier function of cell intestinal epithelial cells, an overexpression vector and application of the overexpression vector. The small interfering RNA provided by the invention is named si-SLC26A3-1, and after a solute-related vector 26A3 gene SLC26A3 is interfered by using the small interfering RNA, mucoprotein, tight junction protein and the like secreted by intestinal epithelial cells are remarkably reduced, which indicates that the barrier function of the intestinal epithelial cells is damaged. After cells are transfected by using the overexpression vector, mucoprotein, tight junction protein and the like secreted by intestinal epithelial cells are remarkably up-regulated, which indicates that the barrier function of the intestinal epithelial cells is enhanced. The small interfering RNA and the overexpression vector provided by the invention can regulate and control the barrier function of the epithelial cells of the pig intestines, and a feasible method is provided for construction and targeted therapy of IBD models of pigs and people based on the similarity of the pigs and the people in the aspects of anatomy, physiology, heredity and the like.
Resumen de: CN118910203A
The invention discloses application of a serum marker in preparation of a kit for evaluating the curative effect of mesenchymal stem cells on Crohn's disease, and relates to the technical field of medical treatment, and the serum marker is a composition at least composed of 4-guanidine butyraldehyde, beta-D-glucopyranosyl gluconic acid and a prolyl arginine isomer 1. Based on an isotope labeled liquid chromatography-mass spectrometry technology, the treatment effectiveness biomarker is screened by detecting the change of serum metabolites before and after the placenta-derived mesenchymal stem cells are used for treating a mouse suffering from the Crohn disease, the diagnosis efficiency of the biomarker is evaluated, and data support is provided for clinical transformation of the mesenchymal stem cells for treating the Crohn disease.
Resumen de: US2024369575A1
Multispecific antibodies comprising a first half antibody comprising a first antigen binding site that binds to a polyubiquitin; and a second half antibody comprising a second antigen binding site that binds a pro-inflammatory protein, such as receptor-interacting protein kinase 1 (RIP1) or receptor-interacting protein kinase 2 (RIP2), as well as methods for using the antibodies, are provided.
Resumen de: WO2024228570A1
The present invention relates to discovery of a target for inhibiting fibrosis in inflammatory bowel disease, and prediction of the progression of fibrosis in inflammatory bowel disease by using same. The present inventors, who are researchers, have found that NOX4 transcripts are detected at low levels in a normal colon, but NOX4 expression is up-regulated in drug-resistant fibrostenosis patients with UC or Crohn's disease (CD) and in a dextran sulfate sodium (DSS)-induced mouse colitis model, and thus it is hypothesized that NOX4 contributes to intestinal fibrosis damage of ulcerative colitis and TGF-β signaling is required to induce fibrosis development. In order to test this hypothesis, the present inventors established Nox4 deficient mice (Nox4-/-) with DSS-induced colitis, and investigated the effect of Nox4 on the response to intestinal injury. This study is expected to be widely used to predict whether fibrosis proceeds in inflammatory bowel diseases and inhibit same.
Resumen de: US2024371490A1
Disclosed are methods for determining an initial or subsequent dose of an anti-tumor necrosis factor α (anti-TNFα) biologic for administering to an individual having an inflammatory condition, based on, in part, determining in the individual a level of one or more time-varying covariates selected from weight, albumin, erythrocyte sedimentation rate (ESR), neutrophil CD64 (nCD64) expression, and combinations thereof, and applying a correction factor to account for the changes in covariates over time. The inflammatory condition may be one selected from an IBD, such as Crohn's Disease (CD) or Ulcerative Colitis (UC), or inflammatory conditions such as uveitis or rheumatoid arthritis.
Resumen de: WO2024227232A1
The present invention relates generally to methods and compositions for treating and/or preventing an inflammatory bowel disease (IBD) and perianal fistulas, the method comprising the administration of therapeutic cells in the subject in need thereof.
Resumen de: CN118899078A
The invention provides a Crohn disease prognosis prediction model construction method based on a medical image and application thereof. Specifically, a deep learning method is used to extract Crohn disease related features from an endoscope graph and a CT image, and a machine learning method is used to combine the Crohn disease related features extracted from the two images with laboratory inspection data to construct a Crohn disease prognosis prediction model. The prediction model provided by the invention can more accurately and efficiently evaluate the prognosis condition of the Crohn disease.
Resumen de: CN118883956A
The invention discloses an application of GATA6 as a target spot in screening of drugs for preventing/treating inflammatory bowel diseases, an application of GATA6 in preparation of drugs for preventing/treating inflammatory bowel diseases, and a drug for preventing/treating inflammatory bowel diseases, and the drug comprises GATA6. Research finds that GATA6 can inhibit fibroblast activation by adjusting Th17 cell differentiation, has a good prevention and treatment effect on IBD, and provides a new strategy for prevention and treatment of IBD.
Resumen de: CN118873490A
The invention relates to the technical field of medical materials, and particularly discloses a pre-gel solution as well as a preparation method, a gelling verification method and application thereof. The pregel solution contains bovine serum albumin or silk fibroin and further contains ferrous ions, the response factor of the pregel solution for forming colloid is active oxygen, and the pregel solution is used for in-situ gel forming and delivery of probiotics and/or drugs while eliminating the active oxygen, so that the problems of ulcerative colitis and intestinal flora imbalance are solved.
Resumen de: CN118873510A
The invention belongs to the technical field of biomedical materials, and particularly relates to a salicylic acid-metal organic framework material wrapped by a probiotic film and loaded with sodium tungstate, a preparation method and application. According to the preparation method, oxsalazine, a tungsten-containing preparation and iron ions are utilized to form a coordination self-assembled salicylic acid-metal organic framework material structure, then the surface of the salicylic acid-metal organic framework material structure is wrapped with a probiotic film through co-extrusion of a porous polycarbonate film, and the salicylic acid-metal organic framework material wrapped with the probiotic film and loaded with the tungsten-containing preparation is prepared. The preparation method is simple and controllable in process and capable of realizing large-scale production, the prepared material can effectively act and be adhered to an inflammation part to play an anti-inflammatory role in an anaerobic microenvironment of intestinal tracts, and meanwhile, iron ions can play a role in noninvasive visual magnetic resonance imaging; and the probiotic film has the effect of regulating the distribution of gastrointestinal flora. Therefore, the framework material disclosed by the invention has a remarkable diagnosis and treatment integrated treatment effect on the inflammatory bowel disease, and is suitable for treatment application of the inflammatory bowel disease.
Resumen de: WO2024227011A1
Blood-based genome-wide DNA methylation profiles are utilized to develop a reliable test to diagnose irritable bowel syndrome (IBS) versus inflammatory bowel disease (IBD), celiac disease and other gastrointestinal diseases that mimic IBS. These methods provide a means to rule out IBS and rule-in active IBD or celiac disease, as well as to rule-out active IBD and celiac disease, and to rule-in IBS.
Resumen de: WO2024224133A1
Predicting non-responsiveness of IBD patients The present invention relates to an in vitro method for predicting the responsiveness of an IBD patient to a therapy with an intracellularly acting immunosuppressive agent of interest, wherein a sample is provided from the IBD patient at an initial period of a treatment with the immunosuppressive agent of interest, said sample comprising effector mononuclear cells, and responsiveness is predicted from the difference between a multidrug ABC transporter activity level in the effector mononuclear cells in said sample and a reference transporter activity level. The method is useful in a treatment of IBD, e.g. in monitoring the progress of the disease or in a decision on a shift from an initial treatment with an agent to another agent like csDMARD or tsDMARD.
Resumen de: WO2023118489A1
A protein comprising an amino acid sequence according to SEQ ID NO: 1, wherein the amino acid in position 4 of SEQ ID NO: 1 is selected from the group consisting of N, S, R, T and I, preferably consisting of N, S and R and wherein the amino acid in position 5 of SEQ ID NO: 1 is selected from the group consisting of R, V, L, F, M, I, H, S, T, A, P and G, with the proviso that the amino acid sequence is not SEQ ID NO: 24.
Resumen de: CN118853870A
The invention relates to the field of medicine, in particular to an inflammatory bowel disease detection marker, a kit and application, the inflammatory bowel disease detection marker is found, the marker is TNFAIP1 and DPP4, cell experiments and animal experiments prove that the TNFAIP1 and DPP4 can cause up-regulation of expression of inflammatory factors, siRNA experiments prove that down-regulation of the TNFAIP1 and DPP4 can cause down-regulation of expression of inflammatory factors, and the siRNA experiments can cause down-regulation of expression of inflammatory factors after down-regulation of the TNFAIP1 and DPP4. And the ROC curve result shows that the TNFAIP1 and DPP4 molecular markers can be used as diagnostic markers of inflammatory bowel diseases, and have important clinical application value.
Nº publicación: CN118852447A 29/10/2024
Solicitante:
LANZHOU VETERINARY RES INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES CHINA CENTER FOR ANIMAL HE
\u4E2D\u56FD\u519C\u4E1A\u79D1\u5B66\u9662\u5170\u5DDE\u517D\u533B\u7814\u7A76\u6240\uFF08\u4E2D\u56FD\u52A8\u7269\u536B\u751F\u4E0E\u6D41\u884C\u75C5\u5B66\u4E2D\u5FC3\u5170\u5DDE\u5206\u4E2D\u5FC3\uFF09
Resumen de: CN118852447A
The invention belongs to the technical field of biology, and particularly relates to a mouse anti-pig IgA single-chain antibody and application thereof.The single-chain antibody comprises a heavy chain variable region and a light chain variable region, the amino acid sequence of the heavy chain variable region is shown as SEQ ID No.1, the amino acid sequence of the light chain variable region is shown as SEQ ID No.3, and the amino acid sequence of the light chain variable region is shown as SEQ ID No.4. The gene sequence of the variable region of the mouse antibody and the gene sequence of the prepared single-chain antibody are compared and analyzed, and the result shows that the gene sequence of the single-chain antibody is basically consistent with the gene sequence of the variable region of the mouse antibody and proves that the gene sequence of the constructed antibody is correct; the single-chain antibody fills the blank of the anti-swine IgA single-chain antibody in the current market, provides a new material for early diagnosis and prevention and control of the swine IgA antibody, and provides a new technical support for controlling epidemic situation transmission of swine diarrhea as soon as possible.
BOPI
Sede Electrónica
